Renal Cell Carcinoma
|Recruiting||Non-Hodgkin's Lymphoma (NHL)||Phase I||NCT01307267|
Phase 1 dose escalation study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb). Safety and dose-finding study of PF-05082566 single agent in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).
|Ages Eligible for Study:||18 Years and older|
|Genders Eligible for Study:||Both|
|Accepts Healthy Volunteers:||No|
Adequate bone marrow, renal, liver and cardiac function
Autoimmune disorders, CNS malignancies
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.